Gabriele cerrone24 Jan 2025 13:25
April 28, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 9,447 ACUT shares in the open market. This brings his total holding to 3,801,226 shares.
Most recent director buy;
LONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 100,000 ACUT shares in the open market. This brings his total holding to 4,719,957 shares.
Forgive me, but how did he get to 4.7m shares? I don’t seem to recall him purchasing that many in total?
Has he done his own placing somehow with the company to give them funds to operate? If so at what price? It would somewhere near correlate to the increased shares in issue.
Massive dilution for shareholders for what seems like a low capital investment but granted if that means giving less away overall if it gets sold for a big wedge then fair play to them If conditions are unfavourable but
CAN YOU UPDATE US PLEASE. If GC has done a 700k share placing (or whatever the hell difference there is in number of shares in issue) then we need to know as it is PRICE SENSITIVE INFORMATION is it not?